Insider Selling: Celldex Therapeutics, Inc. (NASDAQ:CLDX) VP Sells 46,844 Shares of Stock

Celldex Therapeutics, Inc. (NASDAQ:CLDXGet Free Report) VP Richard M. Wright sold 46,844 shares of the stock in a transaction dated Monday, June 3rd. The stock was sold at an average price of $33.72, for a total value of $1,579,579.68. Following the sale, the vice president now owns 20,833 shares of the company’s stock, valued at approximately $702,488.76. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Celldex Therapeutics Price Performance

NASDAQ CLDX opened at $35.11 on Friday. Celldex Therapeutics, Inc. has a 1-year low of $22.11 and a 1-year high of $53.18. The business has a 50 day simple moving average of $38.39 and a two-hundred day simple moving average of $38.56. The stock has a market capitalization of $2.31 billion, a PE ratio of -12.32 and a beta of 1.47.

Celldex Therapeutics (NASDAQ:CLDXGet Free Report) last posted its earnings results on Monday, May 6th. The biopharmaceutical company reported ($0.56) EPS for the quarter, beating analysts’ consensus estimates of ($0.67) by $0.11. Celldex Therapeutics had a negative return on equity of 29.55% and a negative net margin of 2,385.57%. The firm had revenue of $0.16 million during the quarter, compared to the consensus estimate of $1.30 million. On average, analysts anticipate that Celldex Therapeutics, Inc. will post -2.32 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on the company. HC Wainwright restated a “buy” rating and issued a $80.00 price target on shares of Celldex Therapeutics in a research note on Monday. Cantor Fitzgerald reissued an “overweight” rating and issued a $67.00 target price on shares of Celldex Therapeutics in a report on Friday, March 22nd. Finally, Guggenheim raised their target price on shares of Celldex Therapeutics from $72.00 to $90.00 and gave the company a “buy” rating in a research note on Tuesday, February 27th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $66.00.

Check Out Our Latest Stock Report on Celldex Therapeutics

Hedge Funds Weigh In On Celldex Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the business. Virtu Financial LLC bought a new position in shares of Celldex Therapeutics in the 1st quarter valued at about $824,000. Artal Group S.A. purchased a new stake in Celldex Therapeutics during the first quarter valued at approximately $10,618,000. California State Teachers Retirement System lifted its stake in shares of Celldex Therapeutics by 13.5% in the 1st quarter. California State Teachers Retirement System now owns 58,403 shares of the biopharmaceutical company’s stock valued at $2,451,000 after purchasing an additional 6,929 shares during the last quarter. Bayesian Capital Management LP bought a new stake in shares of Celldex Therapeutics in the 1st quarter valued at approximately $470,000. Finally, Public Employees Retirement Association of Colorado purchased a new position in shares of Celldex Therapeutics in the 1st quarter worth approximately $327,000.

Celldex Therapeutics Company Profile

(Get Free Report)

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.

Read More

Receive News & Ratings for Celldex Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.